Table 1.
Baseline demographic and clinical characteristics of treatment-naïve patients
| Characteristic | No. (N = 27) |
% | Median | Range |
|---|---|---|---|---|
| Age ≥70 years | 3 | 11 | 62 | 48-79 |
| Sex | ||||
| Male | 18 | 67 | ||
| Female | 9 | 33 | ||
| ECOG performance status* | ||||
| 0 | 1 | 4 | ||
| 1 | 26 | 96 | ||
| Rai stage† | ||||
| 0, I, or II | 18 | 67 | ||
| III or IV | 9 | 33 | ||
| IGHV mutational status | ||||
| Mutated | 3 | 11 | ||
| Unmutated | 21 | 78 | ||
| Data missing | 4 | 11 | ||
| ZAP-70 (IHC) | ||||
| Negative | 9 | 33 | ||
| Positive | 17 | 63 | ||
| Data missing | 1 | 4 | ||
| β2-microglobulin >3.5 mg/L | 16 | 59 | 4.0 | 2.0-13.1 |
| White blood cell count × 109/μL | 96.6 | 8.8-321.4 | ||
| Hemoglobin, g/dL | 12.6 | 8.1-16.3 | ||
| Platelets × 109/μL | 162 | 77-292 |
IHC, immunohistochemistry.
*
Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing disability.
†
Rai stage 0 indicates low-risk, stage I or II intermediate-risk, and stage III or IV high-risk disease.